As of 2024-12-12, the Intrinsic Value of Supernus Pharmaceuticals Inc (SUPN) is
1.95 USD. This SUPN valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y).
With the current market price of 36.85 USD, the upside of Supernus Pharmaceuticals Inc is
-94.70%.
The range of the Intrinsic Value is 1.35 - 2.40 USD
SUPN Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(65.79) - (4.76) |
(8.86) |
-124.0% |
| DCF (Growth 10y) |
(2.53) - (27.89) |
(4.25) |
-111.5% |
| DCF (EBITDA 5y) |
1.35 - 2.40 |
1.95 |
-94.7% |
| DCF (EBITDA 10y) |
1.95 - 3.90 |
3.01 |
-91.8% |
| Fair Value |
5.41 - 5.41 |
5.41 |
-85.33% |
| P/E |
1.03 - 19.07 |
8.84 |
-76.0% |
| EV/EBITDA |
23.32 - 36.10 |
32.69 |
-11.3% |
| EPV |
37.76 - 47.95 |
42.85 |
16.3% |
| DDM - Stable |
11.46 - 42.32 |
26.89 |
-27.0% |
| DDM - Multi |
3.78 - 10.93 |
5.63 |
-84.7% |
SUPN Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
2,034.86 |
| Beta |
0.79 |
| Outstanding shares (mil) |
55.22 |
| Enterprise Value (mil) |
2,003.18 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.37% |
| Cost of Debt |
4.25% |
| WACC |
5.78% |